Who
Daniel Joseph Apel
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Arrowhead Pharmaceuticals.
In numbers
- Trades disclosed
- 8
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $1.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Jan 2026
- Last trade
- 22 Apr 2026
- Last filed
- 24 Apr 2026
Companies traded
Activity over time
1 Apr – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Apr 2026filed 24 Apr 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $225K3,208 at $70.11 | filing |
| 22 Apr 2026filed 24 Apr 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $82K1,157 at $70.45 | filing |
| 22 Apr 2026filed 24 Apr 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $628K8,730 at $71.92 | filing |
| 22 Apr 2026filed 24 Apr 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $225K3,208 at $70.11 | filing |
| 22 Apr 2026filed 24 Apr 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $82K1,157 at $70.45 | filing |
| 22 Apr 2026filed 24 Apr 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $628K8,730 at $71.92 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
News
Head-To-Head Review: DBV Technologies (NASDAQ:DBVT) vs. Arrowhead Pharmaceuticals (NASDAQ:ARWR)ARWR · dailypolitical.com · 21 Oct 2026Arrowhead Pharmaceuticals (NASDAQ:ARWR) versus Sera Prognostics (NASDAQ:SERA) Head to Head ReviewARWR · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Daniel Joseph Apel; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.